SNY News and Press, Sanofi

2026-03-07 07:41:45 ET More on Pfizer, Johnson & Johnson, etc. Pfizer: Obesity Hype And Vaccine Policy Shocks The Sun Will Shine On Moderna Again - Initiating With A Buy Why Moderna's $950M Patent Bill Is A Small Price For Pipeline Freedom J&J subsidi...

2026-03-06 11:29:20 ET More on Sanofi Need Growing EPS And Dividends? Prescribe Sanofi Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript Sanofi bets up to $1.53B to license blood ca...

2026-03-06 10:45:02 ET More on Pfizer, Merck, etc. Pfizer: Obesity Hype And Vaccine Policy Shocks AbbVie: Stabilizes Near $233 While Testing Resistance Pfizer's Portfolio Renewal In Progress - High Yields For The Patient China approves Pfizer’s GLP-1 d...

2026-03-06 08:00:00 ET Co-authored by Kody's Dividends There's no doubt the world is getting older. Our World in Data There has been a steady trend of the world getting older. Each year, fewer babies are born, and people are living longer. This leads ...

2026-03-05 12:39:19 ET More on Merck KGaA Merck KGaA (MKKGY) Q4 2025 Press Conference Call Transcript Merck KGaA 2025 Q4 - Results - Earnings Call Presentation Merck KGaA 2025 Q4 - Results - Earnings Call Presentation Merck KGaA Non-GAAP EPS of €8.34, ...

2026-03-04 06:57:42 ET More on Sanofi, Sino Biopharmaceutical Limited Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued Sanofi (SAN:CA) Q4 2025 Earnings Call Transcript Sanofi 2025 Q4 - Results - Earnings Call Presentation Sanofi ...

2026-03-03 17:32:49 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results - Slideshow Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Resu...

2026-03-03 15:49:47 ET Denver, Colorado - The morning tape is leaning decisively toward defense-linked manufacturers, advanced materials innovators, and capital-raising energy names, as fresh contract wins and strategic investments reinforce a broader national security narrative. Miss...

2026-02-27 10:49:43 ET More on Sanofi, Regeneron Pharmaceuticals Why Dupixent Keeps Regeneron A Top Big Pharma Pick Sanofi: CEO Leaves With Project Rejuvenation Unfinished, But Stock Undervalued Regeneron: Expect Double-Digit Growth In 2026 Regeneron, Sanofi ...

2026-02-26 13:35:52 ET More on leading drugmakers Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade) Merck: Why Investors Should Remain Bullish Despite Patent Risks ...